View source for URB597

{{chembox
|ImageFile=URB597.svg
|ImageSize=
|IUPACName=[3-(3-carbamoylphenyl)phenyl] N-cyclohexylcarbamate
|OtherNames=
|Section1= {{Chembox Identifiers
|  CASNo=546141-08-6
|  PubChem=1383884
|  SMILES=
|  MeSHName=URB597
  }}
|Section2= {{Chembox Properties
|  Formula=C<sub>20</sub>H<sub>22</sub>N<sub>2</sub>O<sub>3</sub>
|  MolarMass=338.4 g/mol
|  Appearance=
|  Density=
|  MeltingPt=
|  BoilingPt=
|  Solubility=
  }}
|Section3= {{Chembox Hazards
|  MainHazards=
|  FlashPt=
|  Autoignition=
  }}
}}
'''URB597''' is a relatively selective inhibitor of the enzyme [[fatty acid amide hydrolase]] (FAAH).<ref> {{cite journal|title=Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies.|journal= J Med Chem.|date=|first=|last=|coauthors=|volume=47|issue=21|pages=4998|pmid=15456244 |url=|format=|accessdate=2007-06-14|doi=10.1021/jm031140x|author=Mor, Marco|last2=Rivara|first2=S|last3=Lodola|first3=A|last4=Plazzi|first4=PV|last5=Tarzia|first5=G|last6=Duranti|first6=A|last7=Tontini|first7=A|last8=Piersanti|first8=G|last9=Kathuria|first9=S}}</ref><ref> {{cite journal|title=Mechanism of carbamate inactivation of FAAH: implications for the design of covalent inhibitors and in vivo functional probes for enzymes.|journal=Chem Biol.|date=|first=|last=|coauthors=|volume=12|issue=11|pages=1179–87|pmid=16298297 |url=|format=|accessdate=2007-06-14|last1=Alexander|first1=JP|last2=Cravatt|first2=BF|doi=10.1016/j.chembiol.2005.08.011|pmc=1994809}}</ref>  FAAH is the primary degradatory enzyme for the [[endocannabinoid]] [[anandamide]] and, as such, inhibition of FAAH leads to an accumulation of [[anandamide]] in the [[CNS]] and periphery where it activates [[cannabinoid receptor]]s.  In pre-clinical laboratory tests researchers found '''URB597''' increased the production of [[endocannabinoids]] resulting in measurable [[antidepressant]] and [[analgesic]] effects.<ref> {{cite journal|title=The fatty-acid amide hydrolase inhibitor URB597 (cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.|journal= J Pharmacol Exp Ther.|date=|first=|last=|coauthors=|volume=322|issue=1|pages=236–42|pmid=17412883 |url=|format=|accessdate=2007-06-14|last1=Russo|first1=R|last2=Loverme|first2=J|last3=La Rana|first3=G|last4=Compton|first4=TR|last5=Parrott|first5=J|last6=Duranti|first6=A|last7=Tontini|first7=A|last8=Mor|first8=M|last9=Tarzia|first9=G|doi=10.1124/jpet.107.119941}}</ref>

URB597 is also known as KDS-4103. KDS-4103 is being developed by [[Kadmus Pharmaceuticals, Inc.]] for [[clinical trial]]s in [[human]]s.  Kadmus claims, on their website (linked below) that this class of compounds may have antidepressant, anti-anxiety, and pain-killing effects.

==External links==
*[http://www.kadmuspharma.com/ Kadmus Pharmaceuticals official website]
*[http://www.nature.com/nm/journal/v9/n1/full/nm803.html Modulation of anxiety through blockade of anandamide hydrolysis] in ''[[Nature (journal)|Nature]]
*[http://www.cannabis.net/urb597/ New drug acts as marijuana in the brain] at cannabis.net

==References==
<div class='references-small'>
<references/>
</div>

{{Cannabinoids}}

[[Category:Antidepressants]]
[[Category:Benzamides]]
[[Category:Phenol ethers]]
[[Category:Carbamates]]



{{treatment-stub}}
{{cannabinoid-stub}}
[[Category:2Fix]]